Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple therapy shows promise for untreatable liver cancer

NCT ID NCT07081633

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is active but no longer recruiting. Researchers are measuring how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab, tremelimumab, and lenvatinib
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong
This is a phase 2 trial with only 114 participants and no comparison group, so results are preliminary. The drug combination may cause serious side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

114 people

The number who actually took part.

Started

Aug 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed HCC based on histopathological findings from tumor tissues or radiologically findings. * Must not have received prior systemic therapy for unresectable HCC. * Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C. * Child-Pugh Score class A. * ECOG performance status of 0 or 1 at enrollment. * At least 1 measurable lesion per RECSIT 1.1 guidelines Exclusion Criteria: * Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Grade ≥2 from previous anticancer therapy. * History of hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy. * Clinically meaningful ascites. * Patients with main portal vein thrombosis. * Active or prior documented GI bleeding. * Patient currently exhibits symptomatic or uncontrolled hypertension. * Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV) * Uncontrolled intercurrent illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Research Site

    Beijing, 100029, China

  • Research Site

    Beijing, 100044, China

  • Research Site

    Beijing, 100142, China

  • Research Site

    Chengdu, 610078, China

  • Research Site

    Chongqing, 400016, China

  • Research Site

    Guangzhou, 510060, China

  • Research Site

    Guangzhou, 510095, China

  • Research Site

    Guangzhou, 510120, China

  • Research Site

    Guangzhou, 510515, China

  • Research Site

    Hangzhou, 310022, China

  • Research Site

    Hefei, 230022, China

  • Research Site

    Jinan, 250021, China

  • Research Site

    Nanjing, 210009, China

  • Research Site

    Nanjing, 210029, China

  • Research Site

    Ningbo, 315010, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Shanghai, 200438, China

  • Research Site

    Tianjin, 300060, China

  • Research Site

    Wenzhou, 325000, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Xiamen, 361004, China

  • Research Site

    Zhengzhou, 450052, China

  • Research Site

    New Territories, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.